SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide… Read More
Proceeds expected to extend cash runway into H2 2027 VANCOUVER, BC – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, announced that it had entered into… Read More
Trial meets both primary and key secondary endpoints LAVAL, QB – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced positive topline results from the Company’s Phase… Read More
KIRKLAND, QC & MISSISSAUGA, ON – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA®, Merck’s anti-PD-1 therapy, plus LENVIMA®, an orally… Read More
AUR200, a potent recombinant fusion protein, has a clinically validated MOA with a high affinity for targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand) Upon FDA clearance… Read More
